Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 15657440 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Gurumurthy S, Goswami A, Vasudevan KM, Rangnekar VM (2005) Phosphorylation of Par-4 by protein kinase A is critical for apoptosis. Mol Cell Biol 25, 1146-61 15657440
Download Sites

T155-p - PAR-4 (rat)
Orthologous residues
PAR‑4 (human): T163‑p, PAR‑4 (mouse): T156‑p, PAR‑4 (rat): T155‑p
Characterization
 Methods used to characterize site in vivo [32P] bio-synthetic labeling, mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  breast cancer, leukemia, erythroid leukemia, lung cancer, non-small cell lung cancer, prostate cancer
 Relevant cell lines - cell types - tissues:  3T3 (fibroblast), A549 (pulmonary), HEL (erythroid), LNCaP (prostate cell), lung, MCF-10A (breast cell), MCF-7 (breast cell), MD435 (breast cell), MDA-MB231 (breast cell), MEF (fibroblast), NCI-H157 (pulmonary), NCI-H460 (pulmonary), NCI-H838 (pulmonary), PC3 (prostate cell)
 Cellular systems studied:  cell lines, primary cells
 Species studied:  human, mouse
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE PKACA (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE PKACA (human) modification site within consensus motif, phospho-antibody, transfection of wild-type enzyme, pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
cAMP analog increase
mPKI cAMP analog inhibit treatment-induced increase
mPKI decrease
vincristine increase
Downstream Regulation
 Effect of modification (process):  apoptosis, induced, transcription, altered


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.